• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Modeling the Effects of H1N1 Influenza Vaccine Distribution in the United States

tetano

Editor, Senior Moderator
Value Health. 2012 Jan;15(1):158-66. Epub 2011 Dec 3.
Modeling the Effects of H1N1 Influenza Vaccine Distribution in the United States.
Larson RC, Teytelman A.
Source

Engineering Systems Division (ESD), Massachusetts Institute of Technology, Cambridge, MA, USA; Center for Engineering Systems Fundamentals (CESF), Massachusetts Institute of Technology, Cambridge, MA, USA.
Abstract
OBJECTIVE:

We analyzed the effects of the timing of vaccine distribution in 11 US states during the 2009 H1N1 influenza pandemic.
METHODS:

By using reported data on the fraction of patients presenting with flu-related symptoms, we developed a transformation that allowed estimation of the state-specific temporal flu wave curve, representing the number of new infections during each week. We also utilized data describing the weekly numbers of vaccine doses delivered and administered. By using a simple difference equations model of flu progression, we developed two influenza wave curves: first, an "observable" curve that included the beneficial effects of vaccinations, and second, an unobservable curve that depicted how the flu would have progressed with no vaccine administered. We fit the observable curve to match the estimated epidemic curve and early exponential growth associated with R(0), the reproductive number. By comparing the number of infections in each scenario, we estimated the infections averted by the administration of vaccine.
RESULTS:

Southern states experienced peak infection several weeks before northern states, and most of the vaccine was delivered well after the peak of the southern flu wave. Our models suggest that the vaccine had minimal ameliorative impact in the southern states and measurable positive impact in the northern states. Vaccine delivery after peak also results in a smaller fraction of the population's seeking the vaccine.
CONCLUSIONS:

Our analysis suggests that current Centers for Disease Control and Prevention policy of allocating flu vaccine over time in direct proportion to states' populations may not be best in terms of averting nationally the maximum possible number of infections.

Copyright ? 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

PMID:
22264984
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/22264984
 
Back
Top Bottom